<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038462</url>
  </required_header>
  <id_info>
    <org_study_id>Fetal Brain Care</org_study_id>
    <nct_id>NCT05038462</nct_id>
  </id_info>
  <brief_title>Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction</brief_title>
  <official_title>Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigacions Biomèdiques August Pi i Sunyer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of&#xD;
      gestation will be randomized to two equally sized groups: maternal oral supplementation with&#xD;
      Lactoferrin and DHA (Docosahexaenoic acid) or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled trial among pregnant women that have been diagnosed of fetal growth&#xD;
      restriction. These women will be randomized in order to evaluate the impact of maternal&#xD;
      supplementation with Lactoferrin and DHA on the neurodevelopment outcome of their babies.&#xD;
&#xD;
      Main hypothesis: a prenatal intervention based on maternal supplementation with Lactoferrin&#xD;
      and DHA improves neurodevelopment in fetal growth restriction.&#xD;
&#xD;
      Secondary hypothesis are that a prenatal intervention based on maternal supplementation with&#xD;
      Lactoferrin and DHA in fetal growth restriction improves fetal growth and improves perinatal&#xD;
      morbidity and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bayley III scale at 24 months of age</measure>
    <time_frame>24 months of corrected postnatal age</time_frame>
    <description>Bayley III scale is and individually administered instrument that assesses infant development across five domains, including cognitive, language and motor competencies. Parent reported questionnaires are incorporated to assess social-emotional and adaptative behaviors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cortical development</measure>
    <time_frame>34 weeks of gestation</time_frame>
    <description>Assessed by fetal brain magnetic resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal brain volume</measure>
    <time_frame>34 weeks of gestation</time_frame>
    <description>Assessed by fetal brain magnetic resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corpus callosum area</measure>
    <time_frame>Enrolment, 32 and 36 weeks of gestation</time_frame>
    <description>Assessed by fetal neurosonography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal weight</measure>
    <time_frame>Delivery</time_frame>
    <description>Birth weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal morbidity and mortality</measure>
    <time_frame>Perinatal period: period ranging from 32 weeks of gestation (154 days) to the end of the first 4 weeks of neonatal life (28 days)</time_frame>
    <description>Development of one of the following conditions: pregnancy complications, perinatal mortality, metabolic acidosis and major neonatal morbidity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postnatal neurodevelopmental assessment</measure>
    <time_frame>Between 4 and 24 months of corrected postnatal age</time_frame>
    <description>Neurodevelopmental assessment using the Bayley III scale at 24 months of corrected postnatal age, as described in the primary outcome.&#xD;
A complementary neurodevelopmental assessment will be carried out in collaboration with the Speech Acquisition and Perception Groups of the University Pompeu Fabra Barcelona.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse effects</measure>
    <time_frame>Through intervention (supplementation) completion, from enrolment to delivery</time_frame>
    <description>Record of side effects that may appear. Since intervention is usually well tolerated, we do not expect major side effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Maternal supplementation with Lactoferrin and DHA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Product with the same physical appearance and taste as the main intervention but without therapeutic effect</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactoferrin and DHA</intervention_name>
    <description>The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily</description>
    <arm_group_label>Maternal supplementation with Lactoferrin and DHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Product with the same physical appearance and taste as the main intervention but without therapeutic effect</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancies&#xD;
&#xD;
          -  Non-malformed fetus&#xD;
&#xD;
          -  Pregnancies with fetal growth restriction&#xD;
&#xD;
          -  24-32.6 weeks of gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chromosomal or structural abnormalities diagnosed during pregnancy or in the neonatal&#xD;
             period&#xD;
&#xD;
          -  Critical Doppler study suggesting the need for delivery within the next 14 days at the&#xD;
             time of diagnosis: reverse end-diastolic velocity in the umbilical artery or ductus&#xD;
             venosus pulsatility &gt;95th centile&#xD;
&#xD;
          -  Maternal mental or psychiatric disorders&#xD;
&#xD;
          -  Maternal allergy to cow's milk protein&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisenda Eixarch, MD; PhD</last_name>
    <phone>0034 932279333</phone>
    <email>eixarch@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Monterde, MD</last_name>
    <phone>0034 932279333</phone>
    <email>monterde@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Carmina Comas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisenda Eixarch</last_name>
      <email>eixarch@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Elena Monterde</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Irene Ribera</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Luis Hernández</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dexeus-Quirón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerard Albagies</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Míriam Illa</last_name>
      <email>milla@sjdhospitalbarcelona.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General del Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Susana Fernández</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://bcnatalresearch.org/en/projects/fetalbraincare/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigacions Biomèdiques August Pi i Sunyer</investigator_affiliation>
    <investigator_full_name>Elisenda Eixarch Roca</investigator_full_name>
    <investigator_title>Coordinator of Fetal Neurology Unit</investigator_title>
  </responsible_party>
  <keyword>Fetal Growth Retardation</keyword>
  <keyword>Fetal Growth Restriction</keyword>
  <keyword>Intrauterine Growth Restriction</keyword>
  <keyword>Neurodevelopment</keyword>
  <keyword>Lactoferrin</keyword>
  <keyword>DHA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactoferrin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 30, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT05038462/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 30, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT05038462/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

